Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378575013> ?p ?o ?g. }
- W4378575013 abstract "Glioblastoma multiforme (GBM) is associated with remarkably poor prognosis, and its treatment is challenging. This investigation aimed to evaluate the safety of suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cells (ADSCs) carrying herpes simplex virus-thymidine kinase (HSV-TK) gene for the first time in patients with recurrent GBM.This study was a first-in-human, open-label, single-arm, phase I clinical trial with a classic 3 + 3 dose escalation design. Patients who did not undergo surgery for their recurrence were included and received this gene therapy protocol. Patients received the intratumoral stereotactic injection of ADSCs according to the assigned dose followed by prodrug administration for 14 days. The first dosing cohort (n = 3) received 2.5 × 105 ADSCs; the second dosing cohort (n = 3) received 5 × 105 ADSCs; the third dosing cohort (n = 6) received 10 × 105 ADSCs. The primary outcome measure was the safety profile of the intervention.A total of 12 patients with recurrent GBM were recruited. The median follow-up was 16 (IQR, 14-18.5) months. This gene therapy protocol was safe and well tolerated. During the study period, eleven (91.7%) patients showed tumor progression, and nine (75.0%) died. The median overall survival (OS) was 16.0 months (95% CI 14.3-17.7) and the median progression-free survival (PFS) was 11.0 months (95% CI 8.3-13.7). A total of 8 and 4 patients showed partial response and stable disease, respectively. Moreover, significant changes were observed in volumetric analysis, peripheral blood cell counts, and cytokine profile.The present clinical trial, for the first time, showed that suicide gene therapy using allogeneic ADSCs carrying the HSV-TK gene is safe in patients with recurrent GBM. Future phase II/III clinical trials with multiple arms are warranted to validate our findings and further investigate the efficacy of this protocol compared with standard therapy alone.Iranian Registry of Clinical Trials (IRCT), IRCT20200502047277N2. Registered 8 October 2020, https://www.irct.ir/ ." @default.
- W4378575013 created "2023-05-28" @default.
- W4378575013 creator A5013065148 @default.
- W4378575013 creator A5014151924 @default.
- W4378575013 creator A5029236038 @default.
- W4378575013 creator A5040847037 @default.
- W4378575013 creator A5044448802 @default.
- W4378575013 creator A5047035962 @default.
- W4378575013 creator A5064030925 @default.
- W4378575013 creator A5072655907 @default.
- W4378575013 creator A5075842903 @default.
- W4378575013 creator A5076099380 @default.
- W4378575013 date "2023-05-27" @default.
- W4378575013 modified "2023-10-16" @default.
- W4378575013 title "Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial" @default.
- W4378575013 cites W153957434 @default.
- W4378575013 cites W1604428153 @default.
- W4378575013 cites W1977643218 @default.
- W4378575013 cites W1980424217 @default.
- W4378575013 cites W1990738833 @default.
- W4378575013 cites W1994737096 @default.
- W4378575013 cites W2000630426 @default.
- W4378575013 cites W2026575400 @default.
- W4378575013 cites W2028266585 @default.
- W4378575013 cites W2039233796 @default.
- W4378575013 cites W2051771541 @default.
- W4378575013 cites W2074762435 @default.
- W4378575013 cites W2088013637 @default.
- W4378575013 cites W2106623789 @default.
- W4378575013 cites W2107803747 @default.
- W4378575013 cites W2137881268 @default.
- W4378575013 cites W2146482157 @default.
- W4378575013 cites W2148977460 @default.
- W4378575013 cites W2152387543 @default.
- W4378575013 cites W2152815924 @default.
- W4378575013 cites W2161216730 @default.
- W4378575013 cites W2161612641 @default.
- W4378575013 cites W2172477250 @default.
- W4378575013 cites W2587638077 @default.
- W4378575013 cites W2651525809 @default.
- W4378575013 cites W2803201010 @default.
- W4378575013 cites W3004888212 @default.
- W4378575013 cites W3160698757 @default.
- W4378575013 cites W3174421288 @default.
- W4378575013 cites W4211132876 @default.
- W4378575013 cites W4212828223 @default.
- W4378575013 doi "https://doi.org/10.1186/s12967-023-04213-4" @default.
- W4378575013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37245011" @default.
- W4378575013 hasPublicationYear "2023" @default.
- W4378575013 type Work @default.
- W4378575013 citedByCount "0" @default.
- W4378575013 crossrefType "journal-article" @default.
- W4378575013 hasAuthorship W4378575013A5013065148 @default.
- W4378575013 hasAuthorship W4378575013A5014151924 @default.
- W4378575013 hasAuthorship W4378575013A5029236038 @default.
- W4378575013 hasAuthorship W4378575013A5040847037 @default.
- W4378575013 hasAuthorship W4378575013A5044448802 @default.
- W4378575013 hasAuthorship W4378575013A5047035962 @default.
- W4378575013 hasAuthorship W4378575013A5064030925 @default.
- W4378575013 hasAuthorship W4378575013A5072655907 @default.
- W4378575013 hasAuthorship W4378575013A5075842903 @default.
- W4378575013 hasAuthorship W4378575013A5076099380 @default.
- W4378575013 hasBestOaLocation W43785750131 @default.
- W4378575013 hasConcept C104317684 @default.
- W4378575013 hasConcept C111599444 @default.
- W4378575013 hasConcept C126322002 @default.
- W4378575013 hasConcept C141071460 @default.
- W4378575013 hasConcept C142724271 @default.
- W4378575013 hasConcept C143998085 @default.
- W4378575013 hasConcept C171089720 @default.
- W4378575013 hasConcept C198826908 @default.
- W4378575013 hasConcept C2777288759 @default.
- W4378575013 hasConcept C34981463 @default.
- W4378575013 hasConcept C535046627 @default.
- W4378575013 hasConcept C55493867 @default.
- W4378575013 hasConcept C71924100 @default.
- W4378575013 hasConcept C72563966 @default.
- W4378575013 hasConcept C86803240 @default.
- W4378575013 hasConcept C90924648 @default.
- W4378575013 hasConceptScore W4378575013C104317684 @default.
- W4378575013 hasConceptScore W4378575013C111599444 @default.
- W4378575013 hasConceptScore W4378575013C126322002 @default.
- W4378575013 hasConceptScore W4378575013C141071460 @default.
- W4378575013 hasConceptScore W4378575013C142724271 @default.
- W4378575013 hasConceptScore W4378575013C143998085 @default.
- W4378575013 hasConceptScore W4378575013C171089720 @default.
- W4378575013 hasConceptScore W4378575013C198826908 @default.
- W4378575013 hasConceptScore W4378575013C2777288759 @default.
- W4378575013 hasConceptScore W4378575013C34981463 @default.
- W4378575013 hasConceptScore W4378575013C535046627 @default.
- W4378575013 hasConceptScore W4378575013C55493867 @default.
- W4378575013 hasConceptScore W4378575013C71924100 @default.
- W4378575013 hasConceptScore W4378575013C72563966 @default.
- W4378575013 hasConceptScore W4378575013C86803240 @default.
- W4378575013 hasConceptScore W4378575013C90924648 @default.
- W4378575013 hasIssue "1" @default.
- W4378575013 hasLocation W43785750131 @default.
- W4378575013 hasLocation W43785750132 @default.
- W4378575013 hasOpenAccess W4378575013 @default.
- W4378575013 hasPrimaryLocation W43785750131 @default.